Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

1,091 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Long-term outcomes of bictegravir/emtricitabine/tenofovir alafenamide as first-line therapy and as switch strategy in virologically suppressed persons with HIV: data from the ICONA cohort.
d'Arminio Monforte A, Tavelli A, Di Biagio A, Sarmati L, Marchetti GC, Bai F, Cingolani A, Quiros Roldan E, Mussini C, Lichtner M, Vergori A, Piconi S, Orofino G, Fusco FM, Bandera A, Nozza S, Castagna A, Antinori A; ICONA Foundation Study Group. d'Arminio Monforte A, et al. Among authors: castagna a. J Antimicrob Chemother. 2024 Apr 6:dkae081. doi: 10.1093/jac/dkae081. Online ahead of print. J Antimicrob Chemother. 2024. PMID: 38581349
Viral interference between hepatitis B, C, and D viruses in dual and triple infections in HIV-positive patients.
Morsica G, Bagaglio S, Cicconi P, Capobianchi MR, Pellizzer G, Caramello P, Orani A, Moioli C, Rizzardini G, Uberti-Foppa C, Puoti M, Monforte AD; Hepa I.C.o.N.A the Icona Foundation Study Groups. Morsica G, et al. J Acquir Immune Defic Syndr. 2009 Aug 15;51(5):574-81. doi: 10.1097/QAI.0b013e3181add592. J Acquir Immune Defic Syndr. 2009. PMID: 19590432
Risk of developing specific AIDS-defining illnesses in patients coinfected with HIV and hepatitis C virus with or without liver cirrhosis.
d'Arminio Monforte A, Cozzi-Lepri A, Castagna A, Antinori A, De Luca A, Mussini C, Caputo SL, Arlotti M, Magnani G, Pellizzer G, Maggiolo F, Puoti M; Icona Foundation Study Group. d'Arminio Monforte A, et al. Among authors: castagna a. Clin Infect Dis. 2009 Aug 15;49(4):612-22. doi: 10.1086/603557. Clin Infect Dis. 2009. PMID: 19591597
Genotypic/phenotypic patterns of HIV-1 integrase resistance to raltegravir.
Canducci F, Marinozzi MC, Sampaolo M, Boeri E, Spagnuolo V, Gianotti N, Castagna A, Paolucci S, Baldanti F, Lazzarin A, Clementi M. Canducci F, et al. Among authors: castagna a. J Antimicrob Chemother. 2010 Mar;65(3):425-33. doi: 10.1093/jac/dkp477. Epub 2010 Jan 7. J Antimicrob Chemother. 2010. PMID: 20056687
Raltegravir, maraviroc, etravirine: an effective protease inhibitor and nucleoside reverse transcriptase inhibitor-sparing regimen for salvage therapy in HIV-infected patients with triple-class experience.
Nozza S, Galli L, Visco F, Soria A, Canducci F, Salpietro S, Gianotti N, Bigoloni A, Torre LD, Tambussi G, Lazzarin A, Castagna A. Nozza S, et al. Among authors: castagna a. AIDS. 2010 Mar 27;24(6):924-8. doi: 10.1097/QAD.0b013e3283372d76. AIDS. 2010. PMID: 20154578
1,091 results